With growing recognition of the importance of lipoprotein(a) as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), the Lipoprotein(a) Education and Research Forum (Lp(a) Forum) has been established to provide clinicians and researchers worldwide with state-of-the-art information on all aspects of the epidemiology, genetics, and pathophysiology of Lp(a). Moreover, expert insights into the clinical implications for use of current lipid lowering therapies as well as novel Lp(a)-targeted agents currently in development for optimisation of patient care will provide much needed guidance across the healthcare community.
The aims of Lp(a) Forum are to raise awareness of:
- the causal and continuous association between circulating Lp(a) concentrations and cardiovascular risk in populations of different ethnicity;1-3
- the importance of systematic Lp(a) testing at least once in all adults and in younger individuals with family histories of early ASCVD as recommended in North American and European guidance;4-6 and
- ongoing developments in Lp(a)-targeted treatment.
References
- Patel AP, Wang M, Pirruccello JP et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol 2021;41:465–474
- Welsh P, Welsh C, Celis-Morales CA et al. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. Eur J Prev Cardiol 2022;28:1991–2000
- Virani SS, Brautbar A, Davis BC et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study. Circulation 2012;125:241–249
- Pearson GJ, Thanassoulis G, Anderson TJ et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 Aug;37(8):1129-1150
- Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946
- Alebna PL, Mehta A. An update on lipoprotein(a): The latest on testing, treatment and guidelines recommendations. American College of Cardiology, 19 September 2023
